San Diego, CA, United States of America

Venkatachalapathi Yalamorri


Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 44(Granted Patents)


Company Filing History:


Years Active: 1999

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Venkatachalapathi Yalamorri: Innovator in Sulfonamide Research

Introduction

Venkatachalapathi Yalamorri is a notable inventor based in San Diego, CA. He has made significant contributions to the field of medicinal chemistry, particularly in the development of sulfonamides. His work focuses on modulating the activity of the endothelin family of peptides, which play a crucial role in various physiological processes.

Latest Patents

Yalamorri holds a patent for "Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof." This patent details methods for modulating or altering the activity of endothelin peptides. Specifically, it includes N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)-furylsulfonamides, and N-(isoxazolyl)pyrrolylsulfonamides. These compounds are designed to inhibit the binding of endothelin peptides to their receptors, providing potential therapeutic avenues for treating endothelin-mediated disorders.

Career Highlights

Yalamorri is associated with Texas Biotechnology Corporation, where he continues to advance his research. His innovative work has led to the development of effective methods for treating conditions related to endothelin activity. With a total of 1 patent, he has established himself as a key figure in his field.

Collaborations

Throughout his career, Yalamorri has collaborated with esteemed colleagues, including Ming Fai Chan and Chengde Wu. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic agents.

Conclusion

Venkatachalapathi Yalamorri's contributions to sulfonamide research highlight his innovative spirit and dedication to advancing medical science. His work has the potential to impact the treatment of various endothelin-mediated disorders significantly.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…